Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Cancer Risk Scuppers Kyowa Kirin's Autoimmune Disease Drug

Kyowa Kirin halted rocatinlimab trials after finding one confirmed and one suspected Kaposi's sarcoma case, raising safety concerns over the drug's immunological effects.

Summary by Pharmaphorum
Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

2 Articles

PharmaphorumPharmaphorum
Center

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

Read Full Article
biopharmadive.combiopharmadive.com
Center

Kyowa Kirin abandons touted eczema drug following safety review

A month after Amgen gave up on rocatinlimab — which was once seen as a threat to Dupixent — new findings have linked the drug’s mechanism to the onset of a type of skin cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Tuesday, March 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Amgen icon

Amgen

Cancer icon

Cancer

Japan icon

Japan

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal